UMMS Affiliation

Department of Medicine, Division of Rheumatology

Publication Date


Document Type

Article Postprint


Musculoskeletal Diseases | Rheumatology | Skin and Connective Tissue Diseases


OBJECTIVE: Therapeutic response was evaluated among new apremilast, methotrexate, or biologic disease-modifying anti-rheumatic drug (bDMARD) initiators with oligoarticular psoriatic arthritis (PsA).

METHODS: Patients with oligoarticular PsA in the Corrona PsA/Spondyloarthritis Registry initiating treatment with apremilast, methotrexate, or bDMARD and completing 6-month follow-up were included.

RESULTS: In total, 150 patients initiated monotherapy (apremilast: n=34; methotrexate: n=15; bDMARD: n=101). Apremilast initiators had higher baseline disease activity than methotrexate initiators. At follow-up, apremilast initiators experienced numerically greater disease activity improvements than methotrexate initiators and similar improvements to bDMARD initiators.

CONCLUSION: Findings suggest apremilast monotherapy is an effective option for patients with oligoarticular PsA.


arthritis, psoriatic arthritis, TNF receptors, methotrexate

Rights and Permissions

© 2020 The Journal of Rheumatology. This is a pre-copyediting, author-produced PDF of an article accepted for publication in The Journal of Rheumatology following peer review. The definitive publisher-authenticated version is available online at Accepted Manuscript posted with a 12-month embargo as allowed by publisher.

DOI of Published Version



Ogdie A, Liu M, Glynn M, Emeanuru K, Harrold L, Richter S, Guerette B, Mease PJ. Descriptive Comparisons of the Impact of Apremilast and Methotrexate Monotherapy in Oligoarticular Psoriatic Arthritis: the Corrona Psoriatic Arthritis/Spondyloarthritis Registry Results. J Rheumatol. 2020 Nov 15:jrheum.191209. doi: 10.3899/jrheum.191209. Epub ahead of print. PMID: 33191289. Link to article on publisher's site

Journal/Book/Conference Title

The Journal of rheumatology

Related Resources

Link to Article in PubMed

PubMed ID


Available for download on Monday, November 15, 2021